Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al
Medicare Rights Center (@medicarerights) Instagram photos and videos
For expedited same-business-day delivery needs, UPS Next Day Air is available
Do not remove the pen until the plunger has finished moving or you hear a second click
US$ 21.18
US$ 26.24
US$ 24.34
US$ 21.58
US$ 29.79
US$ 20.77
US$ 28.38
US$ 25.88
